Weigert Oliver, Unterhalt Michael, Hiddemann Wolfgang, Dreyling Martin
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
Drugs. 2007;67(12):1689-702. doi: 10.2165/00003495-200767120-00004.
Mantle cell lymphoma is a rare yet well defined subtype of B-cell non-Hodgkin's lymphoma. The correct histological diagnosis of this lymphoma subtype is of the utmost importance; however, it is also a very difficult diagnosis. Clinical management is often complex, and despite the successful introduction of monoclonal antibodies and dose-intensified regimens, including autologous and allogeneic stem cell transplantation strategies, the prognosis remains particularly poor. Recently gained insights into the underlying biology and pathogenesis have unravelled numerous promising molecular targeting strategies; however, their introduction into clinical practice and current treatment algorithms remains a challenge. This article addresses these issues providing relevant information for current state-of-the-art management of patients with mantle cell lymphoma and giving a perspective of upcoming treatment strategies.
套细胞淋巴瘤是一种罕见但定义明确的B细胞非霍奇金淋巴瘤亚型。对这种淋巴瘤亚型进行正确的组织学诊断至关重要;然而,这也是一项非常困难的诊断。临床管理往往很复杂,尽管单克隆抗体和剂量强化方案(包括自体和异基因干细胞移植策略)已成功引入,但预后仍然特别差。最近对潜在生物学和发病机制的深入了解揭示了许多有前景的分子靶向策略;然而,将它们引入临床实践和当前的治疗算法仍然是一项挑战。本文探讨了这些问题,为套细胞淋巴瘤患者的当前先进管理提供了相关信息,并展望了即将到来的治疗策略。